LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 15,000 shares of LeMaitre Vascular stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $33.97, for a total value of $509,550.00. Following the completion of the transaction, the chief executive officer now directly owns 3,390,508 shares in the company, valued at $115,175,556.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

LeMaitre Vascular, Inc. (LMAT) opened at 34.07 on Friday. The firm has a market capitalization of $648.08 million, a price-to-earnings ratio of 48.67 and a beta of 0.65. LeMaitre Vascular, Inc. has a 52 week low of $17.50 and a 52 week high of $36.09. The firm has a 50-day moving average price of $31.97 and a 200 day moving average price of $28.18.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. The company had revenue of $25.80 million for the quarter, compared to analysts’ expectations of $25.42 million. During the same quarter in the prior year, the firm earned $0.14 earnings per share. LeMaitre Vascular’s revenue was up 15.2% compared to the same quarter last year. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current fiscal year.

LeMaitre Vascular declared that its Board of Directors has initiated a stock repurchase program on Thursday, July 27th that permits the company to repurchase $7.50 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to buy up to 1.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its shares are undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Wednesday, August 23rd will be paid a $0.055 dividend. The ex-dividend date is Monday, August 21st. This represents a $0.22 annualized dividend and a yield of 0.65%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 31.88%.

ILLEGAL ACTIVITY NOTICE: “George W. Lemaitre Sells 15,000 Shares of LeMaitre Vascular, Inc. (LMAT) Stock” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/27/george-w-lemaitre-sells-15000-shares-of-lemaitre-vascular-inc-lmat-stock.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in LMAT. Columbia Wanger Asset Management LLC boosted its position in shares of LeMaitre Vascular by 21.0% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,093,903 shares of the medical instruments supplier’s stock valued at $26,943,000 after buying an additional 189,608 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of LeMaitre Vascular by 4.4% in the second quarter. Dimensional Fund Advisors LP now owns 968,232 shares of the medical instruments supplier’s stock valued at $30,228,000 after buying an additional 40,767 shares during the period. Vanguard Group Inc. boosted its position in shares of LeMaitre Vascular by 23.5% in the second quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock valued at $25,462,000 after buying an additional 155,249 shares during the period. Conestoga Capital Advisors LLC boosted its position in shares of LeMaitre Vascular by 45.8% in the second quarter. Conestoga Capital Advisors LLC now owns 565,069 shares of the medical instruments supplier’s stock valued at $17,641,000 after buying an additional 177,379 shares during the period. Finally, State Street Corp boosted its position in shares of LeMaitre Vascular by 25.2% in the second quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock valued at $11,951,000 after buying an additional 77,009 shares during the period. 67.12% of the stock is currently owned by institutional investors.

A number of equities analysts recently commented on LMAT shares. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research note on Tuesday, August 1st. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 price target (up from $29.00) on shares of LeMaitre Vascular in a research note on Sunday, July 30th. Benchmark Co. raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, July 28th. BidaskClub lowered LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Canaccord Genuity lowered LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 price target on the stock. in a research note on Monday, July 10th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $30.17.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.